B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

GLRA1

MOLECULAR TARGET

glycine receptor alpha 1

UniProt: P23415NCBI Gene: 274110 compounds

GLRA1 (glycine receptor alpha 1) is targeted by 10 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting GLRA1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Strychnine3.3026
2Adapalene0.691
3Astemizole Antihistamine drug now withdrawn from0.691
4Cholecalciferol Derivative of 7-dehydroxycholesterol formed by ULTRAVIOLET RAYS breaking of0.691
5cinacalcet0.691
6Colchicine0.691
7Dutasteride0.691
8Fluspirilene0.691
9Picrotoxin0.691
10Sulindac0.691

About GLRA1 as a Drug Target

GLRA1 (glycine receptor alpha 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 10 compounds with documented GLRA1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

GLRA1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.